AR012989A1 - NOVEL SULFONAMIDE INHIBITORS FROM FARNESIL-PROTEIN TRANSFERASE. - Google Patents

NOVEL SULFONAMIDE INHIBITORS FROM FARNESIL-PROTEIN TRANSFERASE.

Info

Publication number
AR012989A1
AR012989A1 ARP980102859A ARP980102859A AR012989A1 AR 012989 A1 AR012989 A1 AR 012989A1 AR P980102859 A ARP980102859 A AR P980102859A AR P980102859 A ARP980102859 A AR P980102859A AR 012989 A1 AR012989 A1 AR 012989A1
Authority
AR
Argentina
Prior art keywords
novel sulfonamide
farnesil
protein transferase
sulfonamide inhibitors
inhibitors
Prior art date
Application number
ARP980102859A
Other languages
Spanish (es)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AR012989A1 publication Critical patent/AR012989A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

Se describen novedosos compuestos de sulfonamida y composiciones farmacéuticas que son inhibidores de la enzima proteína farnesil transferasa.También se describe un método para inhibir la funcion Ras y, por lo tanto, para inhibir eldesarr ollo anormal de las células. El método consiste en administrarel novedoso compuesto de sulfonamida a un sistema biologico. Especificamente, el método inhibe el desarrollo anormal de las células en mamíferos tales comoseres humanos.Novel sulfonamide compounds and pharmaceutical compositions that are inhibitors of the protein farnesyl transferase enzyme are described. A method for inhibiting Ras function and therefore for inhibiting abnormal cell development is also described. The method involves administering the novel sulfonamide compound to a biological system. Specifically, the method inhibits abnormal cell development in mammals such as human beings.

ARP980102859A 1997-06-17 1998-06-16 NOVEL SULFONAMIDE INHIBITORS FROM FARNESIL-PROTEIN TRANSFERASE. AR012989A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87705097A 1997-06-17 1997-06-17

Publications (1)

Publication Number Publication Date
AR012989A1 true AR012989A1 (en) 2000-11-22

Family

ID=25369146

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980102859A AR012989A1 (en) 1997-06-17 1998-06-16 NOVEL SULFONAMIDE INHIBITORS FROM FARNESIL-PROTEIN TRANSFERASE.

Country Status (14)

Country Link
EP (1) EP0989980A1 (en)
JP (1) JP2002507192A (en)
KR (1) KR20010013826A (en)
CN (1) CN1267290A (en)
AR (1) AR012989A1 (en)
AU (1) AU8253698A (en)
CA (1) CA2293358C (en)
CO (1) CO4940475A1 (en)
HU (1) HUP0004627A2 (en)
IL (1) IL133393A0 (en)
NZ (1) NZ501619A (en)
PE (1) PE86199A1 (en)
WO (1) WO1998057949A1 (en)
ZA (1) ZA985218B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6689789B2 (en) 1997-06-17 2004-02-10 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US7517884B2 (en) 1998-03-30 2009-04-14 Kalypsys Inc. Sulfonyl-substituted bicyclic compounds as modulators of PPAR
US7342016B2 (en) 2000-08-30 2008-03-11 Schering Corporation Farnesyl protein transferase inhibitors as antitumor agents
JP2004514717A (en) * 2000-11-29 2004-05-20 シェーリング　コーポレイション Novel farnesyl protein transferase inhibitors
AR052319A1 (en) 2004-10-29 2007-03-14 Kalypsys Inc BICYCLIC COMPOUNDS REPLACED BY SULFONYL IN FUNCTION OF PPAR MODULATORS
BRPI0619282B8 (en) 2005-10-25 2021-05-25 Kalypsys Inc salt, and pharmaceutical composition
WO2008091863A1 (en) 2007-01-23 2008-07-31 Kalypsys, Inc. Sulfonyl-substituted bicyclic compounds as ppar modulators for the treatment of non-alcoholic steatohepatitis
WO2014130534A1 (en) * 2013-02-19 2014-08-28 Icahn School Of Medicine At Mount Sinai Tricyclic heterocycles as anticancer agents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69429440T2 (en) * 1993-10-15 2002-08-08 Schering Corp., Kenilworth TRICYCLIC SULFONAMIDE DERIVATIVES FOR INHIBITING THE G-PROTEIN FUNCTION AND FOR TREATING PROLIFERATIVE DISEASES
IL117798A (en) * 1995-04-07 2001-11-25 Schering Plough Corp Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases and pharmaceutical compositions comprising them
IL117797A0 (en) * 1995-04-07 1996-08-04 Pharmacopeia Inc Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases

Also Published As

Publication number Publication date
CO4940475A1 (en) 2000-07-24
CA2293358C (en) 2008-08-05
PE86199A1 (en) 1999-09-24
EP0989980A1 (en) 2000-04-05
ZA985218B (en) 1998-12-15
AU8253698A (en) 1999-01-04
JP2002507192A (en) 2002-03-05
CA2293358A1 (en) 1998-12-23
IL133393A0 (en) 2001-04-30
HUP0004627A2 (en) 2001-10-28
NZ501619A (en) 2002-02-01
CN1267290A (en) 2000-09-20
WO1998057949A1 (en) 1998-12-23
KR20010013826A (en) 2001-02-26

Similar Documents

Publication Publication Date Title
ES2161291T3 (en) N- (INDOL-2-CARBONIL) AMIDAS AND DERIVATIVES AS INHIBITORS OF THE GLUCOGENO FOSFORILASA.
AR003938A1 (en) TRICYCLIC UREA COMPOUNDS USEFUL FOR THE INHIBITION OF THE FUNCTION OF PROTEIN G AND FOR THE TREATMENT OF PROTEOLYTIC DISEASES, PHARMACEUTICAL COMPOSITION, AND THE USE OF THE SAME FOR THE PREPARATION OF MEDICINES.
MX9206008A (en) PROTEOLYTIC ENZYME INHIBITORS, SACARINE 2-SUBSTITUTED DERIVATIVES.
TR199800825T2 (en) Methyl-2-quinolinone derivatives that inhibit farnesyl protein transfer (imidazol-5-yl).
BR9814340A (en) Indole derivatives as factor xa inhibitors
RU94015838A (en) Derivatives of benzofuranyl- or benzothiophenylalkane carboxylic acid, mixture of their isomers or individual isomers and their salts
RU94031747A (en) Compounds and treatment methods
BR9809342A (en) Compound, pharmaceutical composition, and use of the compound
FI942423A (en) Saccharin derivatives as inhibitors of proteolytic enzyme
BR9811099A (en) Urokinase inhibitors
BR9713178A (en) Spirocyclic metalloprotease inhibitors.
Malemud et al. Identification of neutral proteases in human neutrophil granules that degrade articular cartilage proteoglycan
BR0112337A (en) Phospholipid derivatives of valproic acid and mixtures thereof
AR012989A1 (en) NOVEL SULFONAMIDE INHIBITORS FROM FARNESIL-PROTEIN TRANSFERASE.
Hope et al. Secretory phospholipase A 2 inhibitors and calmodulin antagonists as inhibitors of cytosolic phospholipase A 2
EA200000240A1 (en) CONNECTIONS PREVENTING THE EFFECT OF EARLY TURNING OF MEDICINES
BR9913190A (en) Modulation of multiple lineage protein kinase
CA2266759A1 (en) 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase
EA199800544A1 (en) THIOL DERIVATIVES, possessing inhibitory activity against metallopeptidases
AR009809A1 (en) DERIVATIVES OF 10,13,15-TRIOXATRICICLO [9.2.1 (9.6)] - PENTADECANONE, PROCEDURES FOR ITS PREPARATION AND MEDICINES CONTAINING THESE COMPOUNDS
ES2150461T3 (en) DERIVATIVES OF AMIDINOPHENYLALANINE, PROCESS FOR ITS PREPARATION, ITS EMPLOYMENT AND AGENTS THAT CONTAIN THEM AS ANTICOAGULANTS.
Keraly et al. Inhibition by ticlopidine of PAF-acether-induced in vitro aggregation of rabbit and human platelets
BR9816072A (en) Skin whitening composition containing an ascorbic acid compound
ATE299140T1 (en) FARNESYL PROTEIN TRANSFERASE INHIBITORS
NO20003880D0 (en) Transfectants which are sensitive to reducing conditions, pharmaceutical preparations containing them and their uses

Legal Events

Date Code Title Description
FB Suspension of granting procedure